PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its president and chief executive officer, Will Chou, M.D., will participate in a panel discussion at the Chardan 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 3:30 p.m. Eastern Time in New York City.
The session will focus on advancements and emerging opportunities in genetic medicine. A live webcast of Dr. Chou’s panel will be available via the Investors & News section of Passage Bio’s website at investors.passagebio.com, with a replay accessible for 90 days following the event.
Passage Bio is a clinical-stage biotechnology company developing genetic medicines for patients with neurodegenerative diseases. The company’s lead candidate, PBFT02, is designed to increase progranulin levels in the brain to restore lysosomal function and slow the progression of frontotemporal dementia and related disorders.
Headquartered in Philadelphia, Passage Bio continues to advance its gene therapy pipeline with a focus on one-time treatments that address the root causes of neurological diseases.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.